Ranolazine

Ranexa

Antianginal • Late sodium current inhibitor

QT Risk

Half-life

7 hours

Protein Binding

62%

Metabolized By

CYP3A4, CYP2D6

External

Inhibits late sodium current, reducing intracellular calcium and myocardial oxygen demand

Drug Class

Antianginal

Subclass

Late sodium current inhibitor

Ranexa

Half-life

7 hours

Time for plasma concentration to decrease by 50%

Protein Binding

62%

Fraction bound to plasma proteins

Therapeutic Index

Wide

Margin between therapeutic and toxic doses